research Management and Genetics of Alopecia Areata within the USA: A Cross-Sectional Study of All of Us
Healthcare access for alopecia areata in the USA is unequal among ethnic groups.
Search
for
Sort by
Research
930-960 / 1000+ resultsresearch Parenting styles and psychological effects on children with alopecia areata: exploring family dynamics, anxiety, and depression
Children with alopecia areata often face neglectful parenting, leading to higher anxiety and depression.
research Italian National Registry of Alopecia Areata: an epidemiological study of 699 Italian patients
Alopecia areata is hard to manage and affects quality of life.
research Hair follicle immune privilege in autoimmune and immune-mediated alopecias: paths toward reestablishing immune tolerance
Different types of alopecia cause hair loss due to immune system issues, with some allowing regrowth and others causing permanent loss.
research Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
research Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations
Experts recommend specific treatments for alopecia areata based on age and severity, emphasizing the need for better treatments and acknowledging its psychological impact.
research Stem cell-based therapies for alopecia areata: a narrative review
Stem cell therapies show promise for hair regrowth in alopecia areata but need more research for safety and effectiveness.
research Exosome-Based Therapies for Alopecia Areata: A Systematic Review of Clinical and Experimental Evidence
Exosome-based therapies show promise for treating alopecia areata but need more research.
research Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
research 186 Mechanistic insights into Ritlecitinib-mediated immunomodulation in Alopecia Areata
research Serum Granulysin Levels in Vitiligo and Alopecia Areata: A Potential Biomarker for Disease Activity and Dermoscopic Evaluation
Elevated granulysin levels may indicate disease activity in vitiligo and alopecia areata.
research Effectiveness and safety of baricitinib in severe alopecia areata: 48‐week results
Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
research Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
JAK inhibitors show promise for treating alopecia areata but have serious side effects.
research COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists
Hair specialists vary in testing for alopecia areata, highlighting the need for standard guidelines.
research Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients
Janus Kinase inhibitors are effective and safe for treating alopecia areata, but more research is needed.
research Alopecia Areata
Alopecia areata causes patchy hair loss but hair can regrow on its own.
research Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: A Real‐World Cohort Study
Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.
research National, Regional, and Global Epidemiology of Alopecia Areata: A Systematic Analysis Based on Modeling Study
Alopecia areata affects about 1.93% of people worldwide, with more women affected than men.
research Trichoscopy in the Diagnosis of Alopecia Areata
Trichoscopy helps diagnose and track alopecia areata by examining specific hair and scalp markers.
research Therapeutic potential of oral tofacitinib in alopecia areata: a retrospective study
Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
research Successful Dupilumab Administration in Adolescent with Alopecia Areata and Atopic Dermatitis: Clinical Case
Dupilumab helped an 11-year-old boy regrow hair and reduce skin rashes.
research Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study
Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
research Assessing a measure for Quality of Life in patients with severe Alopecia Areata: a multicentric Italian study
Alopecia Areata severely impacts mental health, causing anxiety and depression, affecting quality of life.
research Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report
Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
research Safety and efficacy of tofacitinib in 97 alopecia areata patients
Tofacitinib is an effective and safe treatment for alopecia areata.
research Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences
Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.
research Insights into Alopecia Areata: A Systematic Review of Prevalence, Pathogenesis, and Psychological Consequences
Alopecia Areata affects people of all ages worldwide, is likely caused by genetic and environmental factors, and can lead to stress and depression, highlighting the need for treatments that address both physical and mental health.
research Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study
Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
research Advances in the mechanism and new therapies of alopecia areata
New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
research 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.